Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC
Clinical trial NCT05611879 · UNKNOWN
Trial details
- NCT number
- NCT05611879
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-03-12
- Primary completion
- 2024-02-29
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.